Clinical Trials
41 trialsNCT03192397 2026-04-14
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT01054196 2026-04-08
Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
NCT00112827 2025-06-06
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT03417284 2025-05-01
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03292263 2024-05-07
ASCT With Nivolumab in Patients With Multiple Myeloma
St. Petersburg State Pavlov Medical University
Phase 1/2 Active not recruiting
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT00566098 2023-05-26
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00995059 2023-01-05
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 1/2 Withdrawn
NCT02780609 2022-11-04
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00784823 2022-08-11
Mel-Vel
Hackensack Meridian Health
Phase 1/2 Completed
NCT03795597 2021-04-26
BuMelCarAuto
Loyola University
Phase 1/2 Unknown
NCT00469209 2020-09-24
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01842308 2020-09-01
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT00985907 2020-06-17
DMV
University of California, San Francisco
Phase 1/2 Terminated
NCT02756728 2020-03-12
A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma
BioInvent International AB
Phase 1/2 Terminated
NCT00003954 2020-02-06
Melphalan and Stem Cell Transplant Before Total-Body Irradiation and Donor Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00085449 2019-11-27
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT00046852 2019-11-04
Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
University of Maryland, Baltimore
Phase 1/2 Completed
NCT00477750 2019-10-11
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00916058 2019-06-04
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma
Weill Medical College of Cornell University
Phase 1/2 Completed
NCT01690143 2018-08-07
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00325416 2018-03-14
Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT01335685 2018-01-23
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT03100877 2017-12-13
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT00054353 2017-10-16
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT02072863 2017-05-02
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
Amgen
Phase 1/2 Completed
NCT01079936 2016-06-06
Lenalidomide and High-Dose Melphalan
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01658904 2016-06-01
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00406978 2016-05-10
MPTD
University of Turin, Italy
Phase 1/2 Completed
NCT02353572 2015-03-09
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
University of Colorado, Denver
Phase 1/2 Terminated
NCT00743288 2014-05-08
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Oncotherapeutics
Phase 1/2 Completed
NCT00334932 2014-01-10
Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00003425 2013-04-26
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
University of Kentucky
Phase 1/2 Completed
NCT00661544 2013-03-04
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00793650 2012-08-30
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
Emory University
Phase 1/2 Terminated
NCT00602706 2011-05-16
Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Mayo Clinic
Phase 1/2 Completed
NCT00388635 2011-01-11
Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
PETHEMA Foundation
Phase 1/2 Completed
NCT00004158 2010-09-21
Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00248430 2010-09-21
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00045136 2009-04-03
Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Completed